Stratifying tumor cell and immune cell PD-L1 groups by tumor stage at RC, patients with an increased PD-L1 score on TCs (IC2/3 vs. IC0: median RFS 6.1 vs. 17.2 months for ≤pT2 tumors; p=0.362; and 7.4 vs. 3.9 months for ≥pT3 tumors; p=0.760) and a negative PD-L1 score on ICs (negative vs. positive: median RFS 7.8 vs. 17.2 months for ≤pT2 tumors; p=0.854; and 3.9 vs. 5.7 months for ≥pT3 tumors; p=0.324) showed a tendency towards shorter RFS, Figure 4E-4H. Here, CD274 is linked to neoplasm.